Get the Stockscreener App
2.305
3.29%
0.025
Gossamer Bio Inc stock is traded at $2.305, with a volume of 225.61K.
It is up +3.29% in the last 24 hours and down -31.94% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$2.28
Open:
$2.35
24h Volume:
225.61K
Relative Volume:
0.06
Market Cap:
$525.25M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-1.7331
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
-2.28%
1M Performance:
-31.94%
6M Performance:
+185.45%
1Y Performance:
+144.04%
1-Day Range:
$2.31
$2.38
1-Week Range:
$2.21
$2.61
52-Week Range:
$0.6617
$3.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
2.31 | 521.85M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.24 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.35 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.07 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.93 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
323.20 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Will Gossamer Bio Inc. bounce back from current supportWeekly Stock Report & Risk Managed Investment Strategies - newser.com
Using portfolio simulators with Gossamer Bio Inc. included2025 Volatility Report & Low Drawdown Momentum Trade Ideas - newser.com
Applying chart zones and confluence areas to Gossamer Bio Inc.July 2025 Catalysts & Fast Exit Strategy with Risk Control - newser.com
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed - Yahoo Finance
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - simplywall.st
Intraday pattern recognizer results for Gossamer Bio Inc.July 2025 Review & Fast Gain Stock Tips - newser.com
Using data tools to time your Gossamer Bio Inc. exit2025 Trading Volume Trends & AI Driven Stock Reports - newser.com
Will Gossamer Bio Inc. (4GB) stock outperform benchmarksWeekly Market Report & Reliable Price Breakout Alerts - newser.com
Using economic indicators to assess Gossamer Bio Inc. potentialEarnings Growth Report & Pattern Based Trade Signal System - newser.com
Real time alert setup for Gossamer Bio Inc. performanceTrade Signal Summary & Safe Capital Allocation Plans - newser.com
Historical volatility pattern of Gossamer Bio Inc. visualizedMarket Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
Evaluating Gossamer Bio Inc. with trendline analysisNew Guidance & Smart Investment Allocation Insights - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Gossamer Bio (NASDAQ:GOSS) - MarketBeat
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
Gossamer Bio (NASDAQ:GOSS) Stock Price Down 5.6%Time to Sell? - MarketBeat
What dividend safety score for Gossamer Bio Inc. stockGlobal Markets & Weekly Return Optimization Alerts - newser.com
How institutional ownership impacts Gossamer Bio Inc. stockWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Smart tools for monitoring Gossamer Bio Inc.’s price actionBear Alert & AI Enhanced Trade Execution Alerts - newser.com
Gossamer Bio Inc. stock trend outlook and recovery pathDividend Hike & Verified Trade Idea Suggestions - newser.com
Advanced analytics toolkit walkthrough for Gossamer Bio Inc.Market Performance Report & AI Powered Market Entry Strategies - newser.com
Is it time to cut losses on Gossamer Bio Inc.July 2025 Levels & Low Drawdown Momentum Ideas - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-10-05 03:04:10 - newser.com
Why institutional investors increase stakes in Gossamer Bio Inc. (4GB) stockWeekly Profit Recap & Verified High Yield Trade Plans - newser.com
Can Gossamer Bio Inc. (4GB) stock withstand sector downturnsWall Street Watch & Stock Portfolio Risk Control - newser.com
What’s next for Gossamer Bio Inc. stock priceDip Buying & Advanced Swing Trade Entry Alerts - newser.com
Is Gossamer Bio Inc. (4GB) stock supported by strong fundamentalsWeekly Profit Recap & Verified Momentum Stock Watchlist - newser.com
What candlestick patterns are forming on Gossamer Bio Inc.July 2025 Trends & High Conviction Trade Alerts - newser.com
Platinum Investment Management Ltd. Cuts Position in Gossamer Bio, Inc. $GOSS - MarketBeat
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):